Flputnam Lifts Stake in Bristol-Myers Squibb Company (BMY) by 52%

Group 1 - Bristol-Myers Squibb Company (NYSE:BMY) is considered an undervalued stock with a wide economic moat, attracting significant investment interest, as evidenced by Flputnam Investment Management Co. increasing its position by 52.4% in Q1, acquiring 76,321 shares for a total of 222,079 shares valued at $13,545,000 [1] - The company offers a forward annual dividend yield of 5.23% and strong cash flow, which are appealing to investors, especially following its recent Q2 results that exceeded expectations [2] - Despite anticipated earnings declines, investors are drawn to Bristol-Myers Squibb for its growth prospects, particularly its use of AI to enhance drug discovery, clinical trials, and cost-efficiency, which is not yet reflected in the stock price [3] Group 2 - Bristol-Myers Squibb is a biopharmaceutical company based in New Jersey, established in 1887, focused on developing innovative solutions for serious diseases [4]